# Esophageal Squamous Cell Carcinoma Market

> Esophageal Squamous Cell Carcinoma Market Research Report Information By Diagnosis and Treatment (Diagnosis and Treatment) by End User (Hospital, Specialty Centers and Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.16%
- **2024:** $ 1.35 Billion
- **2025:** $ 1.46 Billion
- **2035:** $ 3.2 Billion
- **Key Players:** Bristol Myers Squibb (US), Merck & Co (US), Roche (CH), AstraZeneca (GB), Novartis (CH), Eli Lilly and Company (US), Pfizer (US), Bayer (DE), Amgen (US)

**Report ID:** MRFR/LS/10527-CR · **Pages:** 128 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/esophageal-squamous-cell-carcinoma-market-12048

---

## Market Summary

## **Esophageal Squamous Cell Carcinoma Market Overview**

As per MRFR analysis, the Esophageal Squamous Cell Carcinoma Market Size was estimated at 1.35 (USD Billion) in 2024. The Esophageal Squamous Cell Carcinoma Market Industry is expected to grow from 1.46 (USD Billion) in 2025 to 2.96 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.16% during the forecast period (2025 - 2034). The growing increasing prevalence of Achalasia, increased research activities & product approvals, and rising public awareness are driving market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

**In May 2024**, Glenmark Specialty SA, a subsidiary of Glenmark Pharma, revealed a contract for exclusive marketing and distribution with BeiGene, a worldwide oncology firm. According to a statement from the business, Glenmark will be responsible for the registration and commercialization of BeiGene's oncology drugs, Tislelizumab and Zanubrutinib, in India. Tislelizumab is a newly developed monoclonal antibody that targets the PD-1 protein. It has been approved by the NMPA, EMA, and FDA for treating advanced or metastatic esophageal squamous cell carcinoma. Additionally, it is being extensively studied for its potential in treating different types of cancers. 

In March 2024, the FDA granted approval for tislelizumab-jsgr (Tevimbra) as a standalone treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously had systemic chemotherapy, excluding the use of a PD-L1 inhibitor. This information was provided in a press statement by BeiGene, the company responsible for developing the drug. Tislelizumab is expected to be commercially accessible in the United States during the latter part of 2024, as stated by the developers.

The approval was granted after evaluating the outcomes of the phase 3 RATIONALE 302 study (NCT03430843), which compared the effectiveness of tislelizumab as a standalone treatment versus chemotherapy in the second-line treatment for this group of patients. 

**Esophageal Squamous Cell Carcinoma Market Trends**

The increasing prevalence of achalasia aid market growth because achalasia patients have a higher risk of Esophageal Squamous Cell Carcinoma than the general population. The journal Annals of Oesophagus reports that 9 to 10 people per 100,000 people experience achalasia each year.

Furthermore, achalasia can cause food retention, which can lead to bacterial overgrowth, irritation, and chronic inflammation, a pathophysiological process that has been proposed to lead to squamous cell carcinoma. Moreover, two recent meta-analyses found that the incidence rate of squamous cell carcinoma in patients with achalasia ranges from 1.36/1,000 patients-years to 3.12/1,000 patients-years, with risks of 1.5% and 2.8%, respectively.

Moreover, according to the International Agency for Research on Cancer, these rates are 15 and 34 times higher, respectively, than the risk of Esophageal Squamous Cell Carcinoma in the general population. Therefore, increasing prevalence of achalasia will directly affect the market growth of global Esophageal Squamous Cell Carcinoma positively.

## **Esophageal Squamous Cell Carcinoma Market Segment Insights**

### **Esophageal Squamous Cell Carcinoma Diagnosis and Treatment Insights**

The Market segments of Esophageal Squamous Cell Carcinoma, based on diagnosis and treatment, whereas, diagnosis is further segmented into [Endoscopy](../../../reports/endoscopy-devices-market-1967), CT scan, Esophagram, Positron Emission Tomography (PET) and others. Likewise, treatment is further segregated into Surgery, Chemotherapy, [Radiotherapy](../../../reports/radiotherapy-market-1526), Immunotherapy, And Others.

Treatment Segment dominated the market in 2022, while the diagnosis segment is projected to be the fastest-growing during the forecast period, 2023–2030 in the Esophageal Squamous Cell Carcinoma Market revenue. This is due to the increasing prevalence of cancer, introduction of new highly effective medications with lower secondary effects and rising demand for [chemotherapy](../../../reports/chemotherapy-market-5791) for the market's expansion.

**June 2022:**Eli Lilly and Company and Innovent Biologics, Inc. (China), a biopharmaceutical company, announced approval for TYVYT (sintilimab injection) for first line treatment for Esophageal Squamous Cell Carcinoma by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).

### **Esophageal Squamous Cell Carcinoma End User Insights**

The Esophageal Squamous Cell Carcinoma Market segmentation is based on end user which includes hospitals, specialty centers and others.

The hospital segment dominated the market in 2022. This is attributed to the rising prevalence of cancer further require drug discovery and development which fuels the market growth. While the specialty centers segment is projected to be the fastest–growing segment during the forecast period, 2022–2032.

Increased research & development also fuels the market growth of Esophageal Squamous Cell Carcinoma. For instance, according to the research done by Western Reserve University, U.S. in February 2019 found that the most prevalent esophageal cancer in the US, esophageal adenocarcinoma, could be reduced by blocking two molecular pathways that send signals inside cancer cells (EAC). This demonstrated the effectiveness of a novel therapeutic strategy for the treatment of esophageal cancer known as JNK/TGF-beta-targeted therapy.

**Figure 2: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY MOLECULE TYPE, 2022 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

### **Esophageal Squamous Cell Carcinoma Regional Insights**

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Esophageal Squamous Cell Carcinoma market accounted for the largest market share in 2022. This is due to the rising prevalence of esophageal cancer which is raising the demand for the Esophageal Squamous Cell Carcinoma treatment market. Moreover, the increasing investment by major key players in better treatment alternatives is also expected to foster North America’s market growth.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 3: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE BY REGION 2022 & 2032**

Source: Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

Europe Esophageal Squamous Cell Carcinoma market accounts for the second-largest market share due to the rising inclination towards smoke, tobacco, and drink is driving up demand for an advanced treatment option for Esophageal Squamous Cell Carcinoma. Moreover, rising healthcare expenditure is also expected to support the growth of the market. further, the Germany market of Esophageal Squamous Cell Carcinoma was attributed to hold the largest market share, and the Rest of Europe expected to fastest-grow during the forecast period.

The Asia-Pacific Esophageal Squamous Cell Carcinoma market is expected to grow at a significant share from 2023 to 2032. This is due to factors such as the rising incidence of Esophageal Squamous Cell Carcinoma, and the high population of tobacco smoking and alcohol drinking in this region is further expected to boost the market growth. Furthermore, the Increasing physical inactivity and poor lifestyle are also expected to boost the growth of the regional market. Moreover, China market of Esophageal Squamous Cell Carcinoma is expected to hold the largest market share, and Rest of Asia-Pacific market is expected fastest-growing region.

The Rest of the World is segmented into the Middle East, Africa, and Latin America. The market in the above-mentioned regions is likely to witness growth due to strong epidemiological factors, and improving healthcare facilities, increasing awareness about healthy lifestyles. Moreover, improving medical infrastructure in developing and underdeveloped countries, and growing inclination towards advanced treatment solution further drive the market growth of the Esophageal Squamous Cell Carcinoma in the regions clustered as Rest of the World.

**Esophageal Squamous Cell Carcinoma Key Market Players & Competitive Insights**

The Esophageal Squamous Cell Carcinoma Market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as include Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (China) and Seagen Inc. (US) among others, dominate the Market of Esophageal Squamous Cell Carcinoma due to product differentiation, financial stability, strategic developments, and diversified regional presence.

The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the global Esophageal Squamous Cell Carcinoma industry to benefit clients and expand the market of Esophageal Squamous Cell Carcinoma sector is to manufacture locally to reduce operating costs.

Also, AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others.

Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.

**Key Companies in the market of Esophageal Squamous Cell Carcinoma include**

**Esophageal Squamous Cell Carcinoma Industry Developments**

**September 2021:** The FDA has approved Seagen Inc’s TIVDAK (Tisotumab vedotin). It is used to treat cervical cancer that is recurrent or metastatic and Esophageal Squamous Cell Carcinoma cancer. It is also used in women whose cancer got worse during or after treatment with chemotherapy.

**September 2022:** The US FDA has approved AstraZeneca's Imfinzi plus in the US for patients with advanced biliary tract cancer, HCC, BTC, esophageal and gastric cancer.

## **Esophageal Squamous Cell Carcinoma Market Segmentation**

### **Esophageal Squamous Cell Carcinoma Diagnosis and Treatment Outlook**

### **Esophageal Squamous Cell Carcinoma End User Outlook**

### **Esophageal Squamous Cell Carcinoma Regional Outlook**

## Market Drivers

### Advancements in Treatment Modalities

Recent advancements in treatment modalities for esophageal squamous cell carcinoma are significantly influencing the Esophageal Squamous Cell Carcinoma Market. Innovations in surgical techniques, radiation therapy, and chemotherapy have improved patient outcomes and survival rates. The introduction of targeted therapies and immunotherapies has also transformed the treatment landscape, offering new hope to patients. Market data indicates that the adoption of these advanced therapies is on the rise, with a projected increase in market share for companies developing novel treatment options. Furthermore, ongoing clinical trials are exploring combination therapies that may enhance efficacy. As these advancements continue to emerge, they are expected to drive the growth of the Esophageal Squamous Cell Carcinoma Market, attracting investments and fostering competition among key players.

### Investment in Research and Development

Investment in research and development is a significant driver for the Esophageal Squamous Cell Carcinoma Market. Pharmaceutical companies and research institutions are increasingly allocating resources to explore novel therapeutic agents and improve existing treatment protocols. This focus on R&D is driven by the urgent need for more effective therapies, particularly for advanced stages of the disease. Market analysis indicates that the R&D expenditure in oncology, including esophageal squamous cell carcinoma, is projected to increase substantially in the coming years. This investment not only fosters innovation but also enhances collaboration between academia and industry, leading to the development of cutting-edge solutions. As a result, the Esophageal Squamous Cell Carcinoma Market is likely to witness a surge in new product launches and treatment options, catering to the evolving needs of patients.

### Growing Awareness and Screening Programs

The growing awareness of esophageal squamous cell carcinoma and the implementation of screening programs are crucial drivers for the Esophageal Squamous Cell Carcinoma Market. Educational initiatives aimed at both healthcare professionals and the general public have led to increased recognition of the disease's symptoms and risk factors. Consequently, more individuals are seeking medical advice and undergoing diagnostic procedures. Data suggests that regions with established screening programs have reported earlier detection rates, which are associated with improved treatment outcomes. This trend is likely to encourage further investment in diagnostic technologies and therapeutic solutions within the Esophageal Squamous Cell Carcinoma Market. As awareness continues to rise, the demand for effective screening and treatment options is expected to grow, thereby enhancing market dynamics.

### Regulatory Support and Approval Processes

Regulatory support and streamlined approval processes are emerging as vital drivers for the Esophageal Squamous Cell Carcinoma Market. Regulatory agencies are increasingly recognizing the need for expedited pathways for innovative therapies, particularly in oncology. This shift is aimed at addressing the urgent medical needs of patients suffering from esophageal squamous cell carcinoma. Recent initiatives have led to faster review times and approvals for new drugs and treatment modalities, thereby facilitating quicker access to potentially life-saving therapies. Market data suggests that this regulatory environment is conducive to fostering innovation and encouraging investment in the Esophageal Squamous Cell Carcinoma Market. As regulatory frameworks continue to evolve, they are likely to enhance the overall market landscape, promoting the development and availability of effective treatment options.

### Increasing Incidence of Esophageal Squamous Cell Carcinoma

The rising incidence of esophageal squamous cell carcinoma is a pivotal driver for the Esophageal Squamous Cell Carcinoma Market. Factors such as lifestyle changes, dietary habits, and increased tobacco and alcohol consumption contribute to this trend. According to recent data, the incidence rates have shown a notable increase in certain regions, particularly in Asia and parts of Africa. This surge in cases necessitates enhanced diagnostic and therapeutic options, thereby propelling market growth. The growing awareness among healthcare professionals and patients regarding the disease's prevalence further emphasizes the need for effective treatment modalities. As the population ages, the demand for innovative solutions in the Esophageal Squamous Cell Carcinoma Market is likely to escalate, creating opportunities for pharmaceutical companies and healthcare providers alike.

## Future Outlook

The Esophageal Squamous Cell Carcinoma Market is projected to grow at an 8.16% CAGR from 2025 to 2035, driven by advancements in treatment modalities and increasing awareness.

**New opportunities:**

- Development of targeted immunotherapy treatments for personalized patient care. Expansion of telemedicine platforms for remote patient monitoring and consultations. Investment in AI-driven diagnostic tools to enhance early detection rates.

By 2035, the market is expected to exhibit robust growth, reflecting advancements in treatment and increased patient engagement.

## Segment Insights

### By Diagnosis: Endoscopy (Largest) vs. CT Scan (Fastest-Growing)

The Esophageal Squamous Cell Carcinoma Market is primarily dominated by the Endoscopy segment, which plays a crucial role in the diagnosis and assessment of esophageal cancer. It provides real-time visualization of the esophagus, allowing for accurate detection of malignancies, thereby occupying a significant share of the market. Following endoscopy, the CT Scan segment also holds a substantial position, especially in patients where endoscopic procedures may pose risks, thus making it an essential diagnostic alternative. As the healthcare landscape evolves, the growth trajectory of the CT Scan segment is noteworthy, driven by technological advancements and an increasing emphasis on early detection. Additionally, the rising prevalence of esophageal cancer and a greater focus on precise diagnostic tools contribute to the brisk growth of this segment. Innovations in imaging techniques and integration with artificial intelligence further enhance diagnostic accuracy, propelling CT Scans into a faster-growing position within the market.

Endoscopy (Dominant) vs. PET (Emerging)

Endoscopy stands as the dominant technology in the diagnosis of Esophageal Squamous Cell Carcinoma Market, offering direct visualization and biopsy capabilities that are critical for accurate diagnosis. Its robustness stems from a long-standing historical use in clinical practice, coupled with advancements in technique that enhance patient safety and comfort. In contrast, Positron Emission Tomography (PET) represents an emerging technology that, while increasingly relevant, is still establishing its foothold in routine diagnostics. PE's strength lies in its ability to provide metabolic and functional imaging, which aids in distinguishing between benign and malignant lesions. While PET is gaining traction due to increasing awareness of its benefits, endoscopy remains the preferred method for initial diagnosis, demonstrating significant utility in clinical pathways.

### By Treatment: Surgery (Largest) vs. Immunotherapy (Fastest-Growing)

The Esophageal Squamous Cell Carcinoma Market reflects diverse treatment modalities, with Surgery holding the largest share, followed by Chemotherapy and Radiotherapy. Immunotherapy, previously a minor contributor, has shown a significant rise in adoption, reflecting a shift in clinical preferences toward more targeted therapies. Other small segments, like specialized drug treatments and palliative care options, contribute marginally to the overall landscape. As the treatment landscape evolves, a multi-modal approach is increasingly favored, capitalizing on the unique benefits of each modality. Growth trends indicate a robust increase in Immunotherapy, fueled by advancements in biotechnology and increased awareness about personalized medicine. The shift from traditional methods, like Surgery and Chemotherapy, is driven by the quest for better patient outcomes and reduced side effects. Furthermore, regulatory approvals and ongoing clinical trials are enhancing the credibility and acceptance of emerging treatments, positioning Immunotherapy as a vital component in the management of Esophageal Squamous Cell Carcinoma Market.

Surgery (Dominant) vs. Immunotherapy (Emerging)

Surgery remains the dominant treatment choice for Esophageal Squamous Cell Carcinoma Market due to its effectiveness in tumor removal and the availability of minimally invasive techniques. This approach is often preferred for localized cancers, significantly impacting patient survival. However, as clinical research progresses, Immunotherapy is emerging as a promising alternative, leveraging the body's immune system to combat cancer cells. This treatment modality is gaining traction due to its minimal invasiveness and the potential for lasting effects post-treatment. While Surgery is essential for immediate tumor removal, Immunotherapy offers hope for long-term remission, signaling a pivotal shift in treatment paradigms that emphasizes not only addressing tumors but also enhancing the body's innate defenses against cancer.

### By End User: Hospitals (Largest) vs. Specialty Centres (Fastest-Growing)

In the Esophageal Squamous Cell Carcinoma Market, hospitals hold the largest share among the end-user segments. They play a crucial role in patient care, diagnosis, and treatment of the disease. Specialty centers are gaining traction, contributing to innovative treatment options and specialized care tailored for patients suffering from this type of cancer. The presence and accessibility of advanced medical technologies in these facilities further enhance their market position. Growth trends in this segment are largely driven by technological advancements and an increase in patient awareness regarding esophageal cancer treatments. Hospitals benefit from established infrastructure and comprehensive service offerings, while specialty centers are emphasizing precision medicine and multidisciplinary care. As the patient population grows, both segments are anticipated to adapt and expand their services, leading to dynamic changes in the market landscape.

Hospitals (Dominant) vs. Specialty Centres (Emerging)

Hospitals are crucial in the treatment pathway for esophageal squamous cell carcinoma, providing comprehensive care and access to multidisciplinary teams. They often have more resources, including advanced imaging techniques, surgical options, and chemotherapy administration, making them the dominant player in the market. Conversely, specialty centers are emerging with a strong focus on specific cancer types, offering tailored treatment plans and cutting-edge clinical trials. These centers often leverage recent advancements in targeted therapies and immunotherapy, attracting patients seeking specialized care. The competition between these two types of end-users is likely to enhance treatment options available, benefiting patients and driving further innovations in cancer treatment.

## Regional Market Share Analysis

### North America : Leading Market Innovators

The North American market for Esophageal Squamous Cell Carcinoma Market (ESCC) is driven by advanced healthcare infrastructure, high R&D investments, and increasing awareness of cancer screening. The U.S. holds the largest market share at approximately 70%, followed by Canada at around 15%. Regulatory support from agencies like the FDA accelerates the approval of innovative therapies, enhancing treatment options for patients. In this region, the competitive landscape is dominated by major players such as Bristol Myers Squibb, Merck & Co, and Pfizer. These companies are actively involved in developing novel therapies and conducting clinical trials to improve patient outcomes. The presence of leading research institutions further strengthens the market, fostering collaboration between academia and industry to drive innovation in ESCC treatment.

### Europe : Emerging Treatment Landscape

Europe is witnessing significant growth in the Esophageal Squamous Cell Carcinoma Market, driven by increasing incidence rates and advancements in treatment options. Germany and the UK are the largest markets, holding approximately 30% and 25% market shares, respectively. Regulatory bodies like the European Medicines Agency (EMA) are pivotal in facilitating the approval of new therapies, ensuring patient access to innovative treatments. Leading countries in this region include France, Italy, and Spain, alongside Germany and the UK. The competitive landscape features key players such as Roche and AstraZeneca, which are investing heavily in research and development. Collaborative efforts between pharmaceutical companies and healthcare providers are enhancing treatment protocols, ultimately improving patient outcomes in ESCC management. The EMA emphasizes the importance of timely access to effective therapies for cancer patients.

### Asia-Pacific : Rapidly Expanding Market

The Asia-Pacific region is emerging as a significant player in the Esophageal Squamous Cell Carcinoma Market, driven by rising healthcare expenditure and increasing awareness of cancer prevention. China and Japan are the largest markets, accounting for approximately 40% and 20% of the market share, respectively. Government initiatives aimed at improving cancer care and treatment accessibility are key growth drivers in this region. Countries like India and South Korea are also contributing to market expansion, with a growing number of clinical trials and research initiatives. The competitive landscape includes major players such as Novartis and Bayer, which are focusing on innovative therapies tailored to the unique needs of the region. Collaborations between local and international firms are fostering advancements in treatment options, enhancing the overall market landscape for ESCC.

### Middle East and Africa : Emerging Market Potential

The Middle East and Africa region is gradually developing its Esophageal Squamous Cell Carcinoma Market, driven by increasing healthcare investments and rising cancer awareness. South Africa and the UAE are the leading markets, holding approximately 25% and 15% market shares, respectively. Government initiatives aimed at improving healthcare infrastructure are crucial for market growth, as they enhance access to cancer treatments and screenings. In this region, the competitive landscape is characterized by a mix of local and international players, including Amgen and Eli Lilly. The presence of key healthcare organizations is fostering collaborations to improve treatment protocols and patient care. As awareness of ESCC increases, the market is expected to expand, driven by both public and private sector investments in healthcare services.

## Competitive Benchmarking

The Esophageal Squamous Cell Carcinoma Market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as include Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (China) and Seagen Inc. (US) among others, dominate the Market of Esophageal Squamous Cell Carcinoma Market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base. One of the primary business strategies adopted by manufacturers in the global Esophageal Squamous Cell Carcinoma industry to benefit clients and expand the market of Esophageal Squamous Cell Carcinoma Market sector is to manufacture locally to reduce operating costs.

- Hoffmann-La Roche Ltd (Roche) is one of the leading companies in the field of diagnostics and pharmaceuticals. It develops and markets products for the diagnosis & treatment of anemia, cancer, anticoagulation therapy, cardiovascular diseases, diabetes, central nervous system, chlamydia, dermatology, gonorrhea, gout, hepatitis B and C, hemostasis disorders, HIV/AIDS, HPV, infectious diseases, and autoimmune diseases. The company supplies in-vitro diagnostics and drugs for cancer and transplantation. Moreover, it specializes in the field of molecular diagnostics and medicines for oncology, virology, inflammation, metabolism, central nervous system (CNS), clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. In addition, the company has offices and subsidiaries throughout the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

Also, AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.

## Recent News & Developments

**September 2021:** The FDA has approved Seagen Inc’s TIVDAK (Tisotumab vedotin). It is used to treat cervical cancer that is recurrent or metastatic and Esophageal Squamous Cell Carcinoma Market cancer. It is also used in women whose cancer got worse during or after treatment with chemotherapy.

**September 2022:** The US FDA has approved AstraZeneca's Imfinzi plus in the US for patients with advanced biliary tract cancer, HCC, BTC, esophageal and gastric cancer.

## Report Scope

| MARKET SIZE 2024 | 1.352(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.462(USD Billion) |
| MARKET SIZE 2035 | 3.205(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.16% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bristol Myers Squibb (US), Merck & Co (US), Roche (CH), AstraZeneca (GB), Novartis (CH), Eli Lilly and Company (US), Pfizer (US), Bayer (DE), Amgen (US) |
| Segments Covered | Diagnosis and Treatment, End User, Region |
| Key Market Opportunities | Advancements in targeted therapies and immunotherapies enhance treatment options in the Esophageal Squamous Cell Carcinoma Market. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the Esophageal Squamous Cell Carcinoma treatment landscape. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for Esophageal Squamous Cell Carcinoma by 2035?**
A: The projected market valuation for Esophageal Squamous Cell Carcinoma is expected to reach 3.205 USD Billion by 2035.

**Q: What was the overall market valuation for Esophageal Squamous Cell Carcinoma in 2024?**
A: The overall market valuation for Esophageal Squamous Cell Carcinoma was 1.352 USD Billion in 2024.

**Q: What is the expected CAGR for the Esophageal Squamous Cell Carcinoma Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Esophageal Squamous Cell Carcinoma Market during the forecast period 2025 - 2035 is 8.16%.

**Q: Which companies are key players in the Esophageal Squamous Cell Carcinoma Market?**
A: Key players in the Esophageal Squamous Cell Carcinoma Market include Bristol Myers Squibb, Merck & Co, Roche, AstraZeneca, Novartis, Eli Lilly and Company, Pfizer, Bayer, and Amgen.

**Q: What are the main diagnostic segments in the Esophageal Squamous Cell Carcinoma Market?**
A: The main diagnostic segments include Endoscopy, CT Scan, Esophagram, Positron Emission Tomography (PET), and Others, with valuations ranging from 0.15 to 0.9 USD Billion.

**Q: What treatment options are available for Esophageal Squamous Cell Carcinoma?**
A: Treatment options include Surgery, Chemotherapy, Radiotherapy, Immunotherapy, and Others, with valuations between 0.1 and 0.9 USD Billion.

**Q: How do hospitals and specialty centers compare as end users in the Esophageal Squamous Cell Carcinoma Market?**
A: Hospitals and Specialty Centres are significant end users, with valuations of 0.541 USD Billion and 0.405 USD Billion, respectively.

**Q: What is the valuation range for the Endoscopy diagnostic segment?**
A: The valuation range for the Endoscopy diagnostic segment is between 0.5 and 0.9 USD Billion.

**Q: What is the valuation range for the Surgery treatment segment?**
A: The valuation range for the Surgery treatment segment is between 0.5 and 0.9 USD Billion.

**Q: What does the future hold for the Esophageal Squamous Cell Carcinoma Market?**
A: The future of the Esophageal Squamous Cell Carcinoma Market appears promising, with a projected growth to 3.205 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/esophageal-squamous-cell-carcinoma-market-12048*